Information Provided By:
Fly News Breaks for January 18, 2017
NBIX
Jan 18, 2017 | 08:06 EDT
Leerink analyst Paul Matteis lowered his price target for Neurocrine to $65 from $70 after the company announced top-line results from its Phase 2 valbenazine in Adult Tourette's Syndrome. The analyst notes the trial missed its primary endpoint, and says he is lowering his probability of success to 30% from 70%. He reiterates an Outperform rating on the shares.
News For NBIX From the Last 2 Days
NBIX
NBIX
NBIX
NBIX
NBIX
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.